Literature DB >> 18006752

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

Mark J Ratain, Robert H Glassman.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 18006752     DOI： 10.1158/1078-0432.CCR-07-2133

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  24 in total

Review 1.  Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Authors:  Jaap Verweij; Maja de Jonge; Ferry Eskens; Stefan Sleijfer
Journal:  Mol Oncol       Date:  2012-02-16       Impact factor: 6.603

Review 2.  Integrating predictive biomarkers and classifiers into oncology clinical development programmes.

Authors:  Robert A Beckman; Jason Clark; Cong Chen
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

Review 3.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

Review 4.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 5.  Maximum tolerated dose: clinical endpoint for a bygone era?

Authors:  Chris H Takimoto
Journal:  Target Oncol       Date:  2009-04-18       Impact factor: 4.493

Review 6.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 7.  Drug development and clinical trials--the path to an approved cancer drug.

Authors:  Eric H Rubin; D Gary Gilliland
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

Review 8.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 9.  Effective incorporation of biomarkers into phase II trials.

Authors:  Lisa M McShane; Sally Hunsberger; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Authors:  S Postel-Vinay; H-T Arkenau; D Olmos; J Ang; J Barriuso; S Ashley; U Banerji; J De-Bono; I Judson; S Kaye
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.